Cambridge Investment Research Advisors
PHIO icon

Cambridge Investment Research Advisors’s Phio Pharmaceuticals PHIO Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PHIO Stock Details PHIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,581
Closed -$10K – 3504
2024
Q2 		$10K Hold
1,581
– – ﹤0.01% 3291
2024
Q1 		$10K Hold
1,581
– – ﹤0.01% 3286
2023
Q4 		$11K Hold
1,581
– – ﹤0.01% 3164
2023
Q3 		$21K Hold
1,581
– – ﹤0.01% 3082
2023
Q2 		$41K Hold
1,581
– – ﹤0.01% 3093
2023
Q1 		$80K Buy
+1,581
New +$83.5K ﹤0.01% 2990

Other funds holding PHIO

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
NA
Nordwand Advisors Radnor, Pennsylvania $572M AUM 23.09% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Cambridge Investment Research Advisors's PHIO Position: Q3 2024 in Review

Cambridge Investment Research Advisors sold out of Phio Pharmaceuticals (PHIO) in Q3 2024, closing a stake of 1,581 shares — an estimated $10K sold.

Cambridge Investment Research Advisors first reported a position in PHIO in Q1 2023 and held it in 6 quarters. The position peaked at $80K in Q1 2023. 6 funds tracked by Wall St. Rank hold PHIO as of Q3 2024.

  • Cambridge Investment Research Advisors reported no remaining Phio Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Cambridge Investment Research Advisors sold 1,581 Phio Pharmaceuticals shares in Q3 2024, an estimated $10K.
  • Cambridge Investment Research Advisors first reported a position in Phio Pharmaceuticals in Q1 2023 and held it in 6 quarters.
  • Cambridge Investment Research Advisors's Phio Pharmaceuticals position peaked at $80K in Q1 2023.
  • 6 funds tracked by Wall St. Rank held Phio Pharmaceuticals as of Q3 2024.

Based on Cambridge Investment Research Advisors's 13F filing for Q3 2024, filed 28 Oct 2024.